



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0531

Inventors: Brian J. Nickoloff

Serial No.: 09/743,163

Filing Date: January 18, 2001

Examiner: Jessica H. Roark

Group Art Unit: 1644

Title: Method of Treating Disorders by
Modulating the Interaction of Natural
Killer Receptors on T Cells with Their
Respective Ligands

I, Jane Massey Licata, Registration No. 32,257,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: March 11, 2004

Jane Massey Licata
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

() In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

(XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

(XX) Certification in Accordance with §1.97(e) is attached hereto; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: March 11, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **ISPH-0531**

Inventors: **Brian J. Nickoloff**

Serial No.: **09/743,163**

Filing Date: **January 18, 2001**

Examiner: **Jessica H. Roark**

Group Art Unit: **1644**

Title: **Method of Treating Disorders by
Modulating the Interaction of
Natural Killer Receptors on T Cells
with Their Respective Ligands**

I, **Jane Massey Licata**, Registration No. 32,257, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

On this date: March 11, 2004

Jane Massey Licata
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


CERTIFICATION UNDER 37 C.F.R. §1.97(e)

In accordance with 37 C.F.R. §1.97(e), certification is hereby made that:

(XX) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

(XX) No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in connection with a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,




Jane Massey Licata
Registration No. 32,257

Date: March 11, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515




Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. ISPH-0531	Serial No. 09/743,163
	Applicant Brian J. Nickoloff	
	Filing Date January 18, 2001	Group 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BA	Blumberg et al., "Expression of a Nonpolymorphic MHC Class I-Like Molecule, CD1d, by Human Intestinal Epithelial Cells", J. Immunology 1991 147(8):2518-2524 XP-001156220
	BB	Ciccone et al., "Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells", Eur. J. Immunol. 1994 24:1003-1006 XP009011692
	BC	Exley et al., "CD161 (NKR-P1A) Costimulation of CD1d-dependent Activation of Human T Cells Expressing Invariant V α 24J α Q T Cell Receptor α Chains", J. Exp. Med 1998 188(5):867-876 XP-001074739
	BD	Kaufman et al., "Inhibition of selective signaling events in natural killer cells recognizing major histocompatibility complex class I", Proc. Natl. Acad. Sci. USA 1995 92:6484-6488 XP-002243412
	BE	Mieza et al., "Selective Reduction of V α 14 ⁺ NK T Cells Associated with Disease Development in Autoimmune-Prone Mice ¹ ", J. Immunology 1996 156:4035-4040 XP-001159198
	BF	Moretta et al., "P58 Molecules as Putative Receptors for Major Histocompatibility Complex (MHC) Class I Molecules in Human Natural Killer (NK) Cells. Anti-p58 Antibodies Reconstitute Lysis of MHC Class I-protected Cells in NK Clones Displaying Different Specificities", J. Exp. Med. 1993 178:597-604 XP9005922
	BG	Nickoloff et al., "Response of Murine and normal Human Skin to Injection of Allogeneic Blood-Derived Psoriatic Immunocytes", Arch Dermatol. 1999 135:546-552 XP009011742
	BH	Nickoloff et al., "Role of T-cells bearing receptors (CD94, CD158, CD161) for MHC class I and nonclassical MHC-like (CD1d) antigens in psoriasis", J. Investigative Dermatology 1999 page 548 XP009011729
	BI	Nieda et al., "Activation of human V α 24NKT Cells by α -Glycosylceramide in a CD1d-Restricted and V α 24 TCR-Mediated Manner", Human Immunology 1999 60:10-19 XP-001146056

EXAMINER	DATE CONSIDERED
-----------------	------------------------



Form PTO-1119 Modified		Docket No. ISPH-0531	Serial No. 09/743,163
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Brian J. Nickoloff	
		Filing Date January 18, 2001	Group 1644
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BJ	Sumida et al., "Selective Reduction of T Cells Bearing Invariant V α 24J α Q Antigen Receptor in Patients with Systemic Sclerosis", J. Exp. Med. 1995 182:1163-1168 XP-002104249	
	BK	Vitale et al., "Coexpression of two functionally independent p58 inhibitory receptors in human natural killer cell clones results in the inability to kill all normal allogeneic target cells", Proc. Natl. Acad. Sci. USA 1995 92:3536-3540 XP-002243413	
EXAMINER		DATE CONSIDERED	